Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
Date:5/5/2011

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its program highlights and financial results for the first quarter ended March 31, 2011.

"The ANA598 Phase IIb study currently underway will expand the profile of ANA598 in important ways," said Steve Worland, Ph.D., President and CEO of Anadys.  "We expect to increase the ANA598 safety database by approximately 200 patients, with dosing through 24 weeks completed by year-end, and to characterize ANA598's activity in combination with pegylated interferon and ribavirin in treatment-experienced patients.  The acquisition of these data should significantly enhance ANA598's readiness for Phase III activities."

Development Program Highlights

  • ANA598 Phase IIb Study.  During the first quarter, Anadys commenced dosing HCV patients in an ongoing Phase IIb study in which ANA598 is being tested in combination with interferon and ribavirin in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  The Company expects to receive antiviral response data through 12 weeks for all patients, including the 8 week timepoint used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.  Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.  
  • ANA773 Phase IIa Study.  The Company is preparing to commence during the second quarter a 28-day study of ANA773 in combination with riba
    '/>"/>

  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
    (Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
    (Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
    Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
    ... June 3, 2007 - Schering-Plough Corp. announced ... maintenance chemotherapy with,Caelyx (pegylated liposomal doxorubicin hydrochloride),significantly ... with,metastatic breast cancer with infrequent and manageable ... presented,today at the 43rd Annual Meeting of ...
    ... of Largest Ever Phase III Clinical Trial ... /PRNewswire-FirstCall/ --,GlaxoSmithKline today announced final results of ... investigational MAGE-A3,Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3,positive ... Cell Lung Cancer,(NSCLC). These data were presented ...
    Cached Medicine Technology:Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 2Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 3Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 4Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 6
    (Date:9/30/2014)... A new study of 58 ... impact of stress on metabolism after eating a high-fat meal ... a fast food restaurant, about 930 calories and 60 grams ... minutes every hour for 7 hours, conducting the study twice ... had experienced a stressful event in their lives during the ...
    (Date:9/30/2014)... granted new patient appointments to Medicaid beneficiaries and ... care practices (non-FQHCs), in addition to charging less ... 10-state University of Pennsylvania study published this month ... from a previous "secret shopper" study conducted in ... community health clinics that receive federal funding ...
    (Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
    (Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... certified nutrition specialist and best-selling author Mike Geary that is ... totally transform their body into a fat-burning machine in less ... prompting an investigative review. , “In our culture that ... can be hard to decipher what is really fact and ...
    (Date:9/30/2014)... VisitandCare.com reports that revenue for ... more than 79 percent in 2014, marking five straight ... total revenue tripled for its entirety of partnered medical ... has allowed them to partner with plastic surgery ... and privacy — with state-of-the-art surgical atmospheres aimed to ...
    Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
    ... cancer patients of reproductive age, radiation treatment directly to ... direct relationship between certain types of radiation therapy and ... 1 issue of the International Journal of Radiation ... for Radiation Oncology (ASTRO). , Radiation therapy to ...
    ... with schizoaffective disorder who received paliperidone extended release ... improvement in a broad range of schizoaffective symptoms, ... the 12th International Congress on Schizophrenia Research (ICOSR) ... study provide additional evidence for symptomatic improvement of ...
    ... Federally Employed Women (FEW) salutes the House ... included two very important federal worker provisions. An ... Stephen Lynch (D-9-MA) to include the Federal Employees ... legislation during a previous mark up of the ...
    ... researchers say it,s not clear if one causes the ... research provides more evidence of a link between sleeplessness ... whether insomnia actually makes people want to kill themselves. ... problems might be an important contributor to suicidal thinking," ...
    ... release is available in Spanish . ... study of working memory. In terms of information retention, ... affected in diseases such as Alzheimer, and short-term or ... or structure a discourse. This more ephemeral memory is ...
    ... of Children and Adults Living with Autism , ... ... non-profit provider of autism services, Easter Seals believes every ... to a continuum of appropriate autism resources and receive necessary services, ...
    Cached Medicine News:Health News:Some radiation therapy treatments can decrease fertility 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 7Health News:FEW Salutes House for Passing Legislation with Federal Worker Provisions; FERS Sick Leave Credit and FERS Redeposit Approved 2Health News:FEW Salutes House for Passing Legislation with Federal Worker Provisions; FERS Sick Leave Credit and FERS Redeposit Approved 3Health News:Insomnia Linked to Suicidal Thoughts, Attempts 2Health News:Insomnia Linked to Suicidal Thoughts, Attempts 3Health News:Activation of the prefrontal cortex improves working memory 2Health News:The Time to Act for Families is Now -- Will You Act For Autism with Easter Seals? 2Health News:The Time to Act for Families is Now -- Will You Act For Autism with Easter Seals? 3Health News:The Time to Act for Families is Now -- Will You Act For Autism with Easter Seals? 4
    6 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm, 1 x 2. Orientation: Left hand....
    0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish....
    Stainless steel model of the popular Nordan titanium Colibri forceps. Tying platform with 0.12 mm teeth for grasping delicate structures. Flattened round handle with polished finish....
    0.12 mm, 1 x 2 teeth set at 45 degrees with 4.5 mm tying platform. Serrated handle with polished finish....
    Medicine Products: